166 related articles for article (PubMed ID: 10720780)
1. Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals--scientific perspective.
Storer RD
Toxicol Lett; 2000 Mar; 112-113():557-66. PubMed ID: 10720780
[TBL] [Abstract][Full Text] [Related]
2. The in vivo rodent test systems for assessment of carcinogenic potential.
van der Laan JW; Spindler P
Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
[TBL] [Abstract][Full Text] [Related]
3. A perspective on current and future uses of alternative models for carcinogenicity testing.
Goodman JI
Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
[TBL] [Abstract][Full Text] [Related]
4. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.
Storer RD; Sistare FD; Reddy MV; DeGeorge JJ
Toxicol Pathol; 2010 Jan; 38(1):51-61. PubMed ID: 19893055
[TBL] [Abstract][Full Text] [Related]
5. Transgenic assays for mutations and cancer: current status and future perspectives.
Vijg J; van Steeg H
Mutat Res; 1998 May; 400(1-2):337-54. PubMed ID: 9685694
[TBL] [Abstract][Full Text] [Related]
6. Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro.
Thompson KL; Sistare FD
Toxicol Sci; 2003 Aug; 74(2):260-70. PubMed ID: 12730611
[TBL] [Abstract][Full Text] [Related]
7. Regulatory Forum commentary: alternative mouse models for future cancer risk assessment.
Morton D; Sistare FD; Nambiar PR; Turner OC; Radi Z; Bower N
Toxicol Pathol; 2014 Jul; 42(5):799-806. PubMed ID: 23965809
[TBL] [Abstract][Full Text] [Related]
8. Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
Bogdanffy MS; Lesniak J; Mangipudy R; Sistare FD; Colman K; Garcia-Tapia D; Monticello T; Blanset D
Int J Toxicol; 2020; 39(3):198-206. PubMed ID: 32372678
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
10. Current status and use of short/medium-term models for assessment of carcinogenicity of human pharmaceuticals: regulatory perspectives.
van der Laan JW
Toxicol Lett; 2000 Mar; 112-113():567-72. PubMed ID: 10720781
[TBL] [Abstract][Full Text] [Related]
11. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Nambiar PR; Morton D
Toxicol Pathol; 2013; 41(8):1058-67. PubMed ID: 23423820
[TBL] [Abstract][Full Text] [Related]
12. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
13. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
[TBL] [Abstract][Full Text] [Related]
14. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
Mitsumori K; Koizumi H; Nomura T; Yamamoto S
Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
[TBL] [Abstract][Full Text] [Related]
15. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.
Contrera JF; DeGeorge JJ
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):71-80. PubMed ID: 9539006
[TBL] [Abstract][Full Text] [Related]
16. Use of transgenic mice in carcinogenicity hazard assessment.
Jacobson-Kram D; Sistare FD; Jacobs AC
Toxicol Pathol; 2004; 32 Suppl 1():49-52. PubMed ID: 15209403
[TBL] [Abstract][Full Text] [Related]
17. Evaluation on carcinogenicity of chemicals using transgenic mice.
Mitsumori K
Toxicology; 2002 Dec; 181-182():241-4. PubMed ID: 12505318
[TBL] [Abstract][Full Text] [Related]
18. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
19. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
Yamamoto S; Mitsumori K; Kodama Y; Matsunuma N; Manabe S; Okamiya H; Suzuki H; Fukuda T; Sakamaki Y; Sunaga M; Nomura G; Hioki K; Wakana S; Nomura T; Hayashi Y
Carcinogenesis; 1996 Nov; 17(11):2455-61. PubMed ID: 8968063
[TBL] [Abstract][Full Text] [Related]
20. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
Robinson DE; MacDonald JS
Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]